BioWorld

April 8, 2003

ISTA Slides After FDA Issues 'Approvable' Letter On Vitrase

Although it's unclear at this point, the FDA may require a confirmatory study for ISTA Pharmaceuticals Inc.'s Vitrase, a single injection to the eye for vitreous hemorrhage. (BioWorld Today) Read More

Hemosol Laying Off All Staff As It Searches For Path Forward

Human, Murine Newborns Seem To Share Same Gene For Obesity, Hair, Wrinkles In Rare Disorder

Epigenomics Raises EUR21M To Fund Work In DNA Methylation

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...